EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Extended-release Hydrocortisone Formulations—Is There a Clinically Meaningful Benefit?

Sandra D Steintorsdottir, Marianne Øksnes, Anders P Jørgensen, Eystein S Husebye iD

The Journal of Clinical Endocrinology & Metabolism · 18.02.2025 · 110 (3) · e566-e573

DOI: 10.1210/clinem/dgae822 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 03.12.2024. Verfasst von Sandra D Steintorsdottir und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, University of Bergen, Bergen N-5020, Norway. Hauptthemen laut MEDLINE: Hydrocortisone, Adrenal Insufficiency, Hormone Replacement Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: KlinBeforsk, The Regional Health Authorities of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite best practice replacement therapy with corticosteroids, patients with adrenal insufficiency report diminished quality of life and face increased mortality and morbidity. Conventional formulations of hydrocortisone have short half-lives (about 90 minutes) requiring multiple dosing during the day. Since 2011, extended-release hydrocortisone (ER-HC) formulations have been available enabling once-, sometimes twice-daily dosing. Most studies comparing ER-HC formulations with conventional hydrocortisone therapy report reduction in body weight, blood pressure and glucose levels, and improved quality of life. However, it is still unclear if the reported beneficiary effects are due to differences in cortisol exposure or alterations in pharmacokinetics. Here, we review studies comparing conventional and ER-HC treatment in adrenal insufficiency and discuss whether these novel formulations are safe and offer clinically significant benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrocortisoneAdrenal InsufficiencyHormone Replacement TherapyHumansDelayed-Action PreparationsQuality of LifeTreatment Outcome

Stichwörter der Autor:innen

Addison's diseaseadrenal insufficiencyextended-release hydrocortisone (ER-HC)glucocorticoid replacement therapyimmediate-release hydrocortisone (IR-HC)

Substanzen

HydrocortisoneDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Clinical Medicine, University of Bergen, Bergen N-5020, Norway.
  • Department of Medicine, Haukeland University Hospital, Bergen N-5021, Norway.
  • Department of Endocrinology, Oslo University Hospital, Oslo N-0424, Norway.
  • Faculty of Clinical Medicine, University of Oslo, Oslo N-0318, Norway.

ORCID-Profile: Eystein S Husebye

Förderung

  • KlinBeforsk
  • The Regional Health Authorities of Norway

Zitieren

APA

Steintorsdottir, S. D., Øksnes, M., Jørgensen, A. P., & Husebye, E. S. (2025). Extended-release Hydrocortisone Formulations—Is There a Clinically Meaningful Benefit?. The Journal of Clinical Endocrinology & Metabolism, 110(3), e566-e573. https://doi.org/10.1210/clinem/dgae822

Vancouver

Steintorsdottir SD, Øksnes M, Jørgensen AP, Husebye ES. Extended-release Hydrocortisone Formulations—Is There a Clinically Meaningful Benefit?. The Journal of Clinical Endocrinology & Metabolism. 2025;110(3):e566-e573. doi:10.1210/clinem/dgae822

BibTeX
@article{Steintorsdottir2025,
  author = {Steintorsdottir, Sandra D and Øksnes, Marianne and Jørgensen, Anders P and Husebye, Eystein S},
  title = {Extended-release Hydrocortisone Formulations—Is There a Clinically Meaningful Benefit?},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {3},
  pages = {e566--e573},
  doi = {10.1210/clinem/dgae822}
}
Kostenlos starten →